|
GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
|
JPH07504184A
(ja)
|
1992-02-20 |
1995-05-11 |
ジェイムズ・ブラック・ファウンデーション・リミテッド |
コレストシストキニン抑制剤としてのビシクロ［２，２，２］オクタン誘導体
|
|
CN1120845A
(zh)
|
1993-04-15 |
1996-04-17 |
格拉克索有限公司 |
具有cck和/或胃泌素拮抗活性的1，5-苯并二氮杂䓬衍生物
|
|
AU707748B2
(en)
|
1994-03-25 |
1999-07-22 |
Isotechnika Inc. |
Enhancement of the efficacy of drugs by deuteration
|
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
|
TW369529B
(en)
|
1994-04-14 |
1999-09-11 |
Glaxo Inc |
5-heterocyclo-1,5-benzodiazepine derivatives, pharmaceutical composition comprising the same and process for the preparation thereof
|
|
AU2446295A
(en)
|
1994-04-15 |
1995-11-10 |
Glaxo Inc. |
A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
|
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
EP2218734B1
(en)
|
1996-04-12 |
2013-06-05 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
|
BR0114888A
(pt)
|
2000-10-26 |
2003-12-09 |
Sanofi Synthelabo |
Derivados de triazol e composições farmacêuticas compreendendo os mesmos
|
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
|
US7112567B2
(en)
|
2001-02-16 |
2006-09-26 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
|
EP1558607B1
(en)
*
|
2002-10-30 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
|
US7834013B2
(en)
|
2003-11-19 |
2010-11-16 |
Glaxosmithkline Llc |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
|
|
EP1731505B1
(en)
|
2004-03-30 |
2015-01-14 |
Takeda Pharmaceutical Company Limited |
Alkoxyphenylpropanoic acid derivatives
|
|
AP2006003768A0
(en)
|
2004-05-25 |
2006-10-31 |
Pfizer Prod Inc |
TetraazabenzoÄeÜazulene derivatives and analogs tehereof
|
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
|
JP2008528590A
(ja)
|
2005-01-28 |
2008-07-31 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病性二環式化合物
|
|
AU2006210954A1
(en)
|
2005-01-31 |
2006-08-10 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
|
ES2361095T5
(es)
|
2005-05-04 |
2021-11-23 |
Zealand Pharma As |
Análogos del péptido 2 tipo glucagón (GLP-2)
|
|
ATE445612T1
(de)
|
2005-06-02 |
2009-10-15 |
Hoffmann La Roche |
Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5
|
|
EP1948785B1
(en)
|
2005-10-24 |
2014-01-15 |
Janssen Biotech, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
|
EP1980148B1
(en)
|
2006-01-31 |
2013-03-20 |
Takeda Pharmaceutical Company Limited |
Genetically modified animal and use thereof
|
|
EP2010519B1
(en)
|
2006-04-14 |
2011-07-06 |
Merck Sharp & Dohme Corp. |
Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
|
|
US7858629B2
(en)
|
2006-04-14 |
2010-12-28 |
Merck Sharp & Dohme Corp. |
Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators
|
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
ATE552245T1
(de)
|
2006-05-15 |
2012-04-15 |
Merck Sharp & Dohme |
Antidiabetische bicyclische verbindungen
|
|
EP2076604A4
(en)
|
2006-08-31 |
2009-09-02 |
Centocor Ortho Biotech Inc |
GLP-2 MIMIC BODIES, POLYPEPTIDES, COMPOSITIONS, PROCESSES AND USES
|
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
|
EP2079467B1
(en)
|
2006-10-31 |
2015-11-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
MX2009004701A
(es)
|
2006-11-08 |
2009-05-21 |
Zealand Pharma As |
Analogos selectivos del peptido 2 similar al glucagon.
|
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
|
AU2007325315A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys Inc |
Heterocyclic modulators of TGR5
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
CN101679476B
(zh)
|
2007-01-19 |
2014-05-07 |
英特塞普特医药品公司 |
23取代的胆汁酸作为tgr5调节剂及其使用方法
|
|
WO2008091631A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck & Co., Inc. |
Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
JP2010539152A
(ja)
|
2007-09-10 |
2010-12-16 |
プロシディオン・リミテッド |
代謝障害の治療のための化合物
|
|
RU2443699C2
(ru)
|
2007-09-20 |
2012-02-27 |
Айрм Ллк |
Соединения и композиции в качестве модуляторов активности gpr119
|
|
CN101796017A
(zh)
|
2007-09-21 |
2010-08-04 |
塞诺菲-安万特股份有限公司 |
(羧基亚烷基苯基)苯基草酰胺、其生产方法以及作为药物的用途
|
|
RU2010115747A
(ru)
|
2007-09-21 |
2011-10-27 |
Санофи-Авентис (Fr) |
(циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства
|
|
EP2216340B1
(en)
|
2007-10-17 |
2012-12-12 |
Universidad De Córdoba |
Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligonucleotide pairs for detection thereof by pcr
|
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
|
PL2206707T3
(pl)
|
2007-10-24 |
2015-01-30 |
Astellas Pharma Inc |
Związek azolokarboksamidowy lub jego sól
|
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
|
ME02338B
(me)
|
2007-10-26 |
2013-02-28 |
Japan Tobacco Inc |
Spiro-ciklično jedinjenje i njegova upotreba u medicinske svrhe
|
|
JP5542058B2
(ja)
|
2007-10-29 |
2014-07-09 |
メルク・シャープ・アンド・ドーム・コーポレーション |
抗糖尿病性三環式化合物
|
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックＩｐマネジメント株式会社 |
発光装置および照明器具
|
|
EA018703B1
(ru)
|
2008-04-07 |
2013-10-30 |
Айрм Ллк |
Соединения и композиции в качестве модуляторов активности gpr119
|
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
CN105037476B
(zh)
|
2008-07-30 |
2018-06-12 |
英特塞普特医药品公司 |
Tgr5调节剂及其使用方法
|
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US20110171164A1
(en)
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
|
AU2009314200B2
(en)
|
2008-11-17 |
2011-11-17 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
|
ES2774368T3
(es)
|
2008-11-19 |
2020-07-20 |
Intercept Pharmaceuticals Inc |
Moduladores de TGR5 y métodos de uso de los mismos
|
|
SG10201400162QA
(en)
|
2008-11-19 |
2014-05-29 |
Intercept Pharmaceuticals Inc |
Tgr5 modulators and methods of use thereof
|
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
|
JP2012515782A
(ja)
|
2009-01-23 |
2012-07-12 |
シェーリング コーポレイション |
抗糖尿病性架橋および縮合化合物
|
|
CA2749930A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
AU2010206783A1
(en)
|
2009-01-23 |
2011-07-28 |
Merck Sharp & Dohme Corp. |
Pentafluorosulpholane-containing antidiabetic compounds
|
|
AR075051A1
(es)
|
2009-02-05 |
2011-03-02 |
Schering Corp |
Compuestos antidiabeticos que contienen ftalazina
|
|
US8785488B2
(en)
|
2009-02-12 |
2014-07-22 |
Exelixis Patent Company Llc |
Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity
|
|
EP2399914A4
(en)
|
2009-02-18 |
2012-08-29 |
Takeda Pharmaceutical |
FUSED HETEROCYCLIC CORE COMPOUND
|
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
|
RU2011147232A
(ru)
|
2009-04-22 |
2013-05-27 |
Астеллас Фарма Инк. |
Производное карбоновой кислоты
|
|
EP2440541A1
(en)
|
2009-06-09 |
2012-04-18 |
Takeda Pharmaceutical Company Limited |
Novel fused cyclic compound and use thereof
|
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
WO2011052756A1
(ja)
|
2009-10-30 |
2011-05-05 |
持田製薬株式会社 |
新規３－ヒドロキシ－５－アリールイソキサゾール誘導体
|
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
|
AR077851A1
(es)
|
2009-12-11 |
2011-09-28 |
Exelixis Inc |
Agonistas del tgr5
|
|
CA2785674A1
(en)
|
2009-12-25 |
2011-06-30 |
Mochida Pharmaceutical Co., Ltd. |
Novel 3-hydroxy-5-arylisothiazole derivative
|
|
WO2011146324A1
(en)
|
2010-05-18 |
2011-11-24 |
Merck Sharp & Dohme Corp. |
Spiro isoxazoline compounds as sstr5 antagonists
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
BR112013001571A2
(pt)
|
2010-07-23 |
2016-05-10 |
Connexios Life Sciences Pvt Ltd |
composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
|
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
|
JP5908478B2
(ja)
|
2010-08-30 |
2016-04-26 |
エヌピーエス ファーマシューティカルズ インコーポレイテッドＮｐｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
|
|
US9040525B2
(en)
|
2010-10-08 |
2015-05-26 |
Mochida Pharmaceutical Co., Ltd. |
Cyclic amide derivative
|
|
JPWO2012070554A1
(ja)
|
2010-11-22 |
2014-05-19 |
国立大学法人京都大学 |
ペプチド
|
|
US20120302566A1
(en)
|
2010-12-01 |
2012-11-29 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
|
PH12013501718A1
(en)
|
2011-02-17 |
2013-10-07 |
Takeda Pharmaceuticals Co |
Production method of optically active dihydrobenzofuran derivative
|
|
US8957062B2
(en)
*
|
2011-04-08 |
2015-02-17 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
|
CA2832581C
(en)
|
2011-04-08 |
2022-08-23 |
Yumei Xiong |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
|
US8557766B2
(en)
|
2011-04-27 |
2013-10-15 |
Mochida Pharmaceutical Co., Ltd. |
3-hydroxyisothiazole 1-oxide derivatives
|
|
JP2014518853A
(ja)
|
2011-04-28 |
2014-08-07 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規な二環式窒素含有ヘテロアリールｔｇｒ５受容体調節因子
|
|
EP2720544B1
(en)
*
|
2011-06-16 |
2016-12-21 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
|
AR087451A1
(es)
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
|
AU2012339870B2
(en)
*
|
2011-11-15 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as GPR119 agonists
|
|
KR20140107539A
(ko)
|
2011-12-21 |
2014-09-04 |
알데릭스, 인코포레이티드 |
비-전신성 tgr5 작용제
|
|
AU2012365706B2
(en)
|
2012-01-12 |
2015-08-20 |
Jiangsu Hengrui Medicine Co., Ltd. |
Polycyclic derivatives, preparation method and medical uses thereof
|
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
|
JP6095580B2
(ja)
|
2012-02-13 |
2017-03-15 |
武田薬品工業株式会社 |
芳香環化合物
|
|
EP2816032A4
(en)
|
2012-02-13 |
2015-09-30 |
Takeda Pharmaceutical |
AROMATIC RING CONNECTION
|
|
EP2820005A1
(en)
|
2012-02-28 |
2015-01-07 |
Piramal Enterprises Limited |
Phenyl alkanoic acid derivatives as gpr agonists
|
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規５－アリール－１，２－チアジナン誘導体
|
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
EP2900242A4
(en)
*
|
2012-09-26 |
2016-06-29 |
Merck Sharp & Dohme |
SUBSTITUTED CYCLOPROPYL COMPOUNDS
|
|
JP6272888B2
(ja)
|
2012-10-26 |
2018-01-31 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
胆汁酸誘導体を調製するためのプロセス
|
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Ｌｇ化學股份有限公司 |
Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
|
MX2015006710A
(es)
|
2012-11-28 |
2016-01-15 |
Intercept Pharmaceuticals Inc |
Tratamiento de las enfermedades pulmonares.
|
|
MA38170B1
(fr)
|
2012-11-28 |
2017-04-28 |
Boehringer Ingelheim Int |
Nouveaux acides indanyloxydihydrobenzofuranylacétiques
|
|
US20140163025A1
(en)
|
2012-12-07 |
2014-06-12 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
|
JP6314335B2
(ja)
|
2013-02-06 |
2018-04-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新しいインダニルオキシジヒドロベンゾフラニル酢酸
|
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
|
WO2014187343A1
(zh)
|
2013-05-22 |
2014-11-27 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
|
US20160151486A1
(en)
|
2013-06-13 |
2016-06-02 |
Fast Foward Pharmaceuticals B.V. |
CD40 Signalling Inhibitor and a Further Compound, Wherein the Further Compound is a Bile Acid, a Bile Acid Derivative, an TGR5-Receptor Agonist, an FXR Agonist or a Combination Thereof, for the Treatment of Chronic Inflammation, and the Prevention of Gastrointestinal Cancer or Fibrosis
|
|
WO2015000412A1
(zh)
|
2013-07-02 |
2015-01-08 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
|
WO2015010655A1
(zh)
|
2013-07-26 |
2015-01-29 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
|
DK3027642T3
(da)
|
2013-07-31 |
2020-11-02 |
Amgen Inc |
Vækstdifferentieringsfaktor 15 (gdf-15)-konstruktioner
|
|
HUE039259T2
(hu)
|
2013-08-09 |
2018-12-28 |
Takeda Pharmaceuticals Co |
Aromás vegyület
|
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
|
EP3036237A4
(en)
|
2013-08-23 |
2017-01-25 |
Fujian Haixi Pharmaceuticals Co. Ltd |
Carboxylic acid compounds in treatment of diabetes mellitus
|
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
|
JP6533778B2
(ja)
|
2013-09-26 |
2019-06-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｇｐｒ４０アゴニストとしてのインダニルオキシジヒドロベンゾフラニル酢酸誘導体を調製するための方法および中間体
|
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
|
IN2013MU03577A
(enrdf_load_stackoverflow)
|
2013-11-14 |
2015-07-31 |
Cadila Healthcare Ltd |
|
|
ES2747973T3
(es)
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
|
JP6441928B2
(ja)
|
2013-11-28 |
2018-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規インダニルオキシフェニルシクロプロパンカルボン酸
|
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎三唑并吡啶化合物
|
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
|
US9809592B2
(en)
|
2014-01-10 |
2017-11-07 |
Eli Lilly And Company |
Isopropyl triazolo pyridine compounds
|
|
ES2653425T3
(es)
|
2014-01-10 |
2018-02-07 |
Eli Lilly And Company |
Compuestos de fenil-triazolo-piridina
|
|
WO2015119899A1
(en)
|
2014-02-06 |
2015-08-13 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
|
WO2015160772A1
(en)
|
2014-04-15 |
2015-10-22 |
Janssen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of tgr5
|
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
|
SI3626725T1
(sl)
|
2014-05-29 |
2023-04-28 |
Bar Pharmaceuticals S.R.L. |
Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1
|
|
US20170204149A1
(en)
|
2014-06-23 |
2017-07-20 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof
|
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
|
EP3177287B1
(en)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
EP3177282B1
(en)
|
2014-08-08 |
2021-10-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
|
US20180236064A1
(en)
|
2014-10-03 |
2018-08-23 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之ｇｐｒ４０促效劑的經取代苯并噻吩基衍生物
|
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
|
KR20170078668A
(ko)
|
2014-10-31 |
2017-07-07 |
구브라 에이피에스 |
이중 glp-1r 및 glp-2r 작용제 활성을 갖는 조성물 및 펩티드
|
|
KR20170094184A
(ko)
|
2014-11-06 |
2017-08-17 |
이난타 파마슈티칼스, 인코포레이티드 |
Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
BR112017017238A2
(pt)
|
2015-02-11 |
2018-04-10 |
Enanta Pharm Inc |
análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
|
|
EP3277286B1
(en)
|
2015-03-31 |
2021-04-21 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
|
|
PT3310801T
(pt)
|
2015-06-24 |
2021-06-18 |
Intercept Pharmaceuticals Inc |
Moduladores de tgr5 e métodos de utilização dos mesmos
|
|
JP6772133B2
(ja)
|
2015-07-02 |
2020-10-21 |
サントリーホールディングス株式会社 |
Ｇｌｐ−２分泌促進用組成物
|
|
AR105269A1
(es)
|
2015-07-06 |
2017-09-20 |
Novo Nordisk As |
Péptidos y derivados de péptidos de colecistoquinina (cck) y sus usos
|
|
WO2017025368A1
(en)
|
2015-08-07 |
2017-02-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
WO2017027396A1
(en)
|
2015-08-07 |
2017-02-16 |
Intercept Pharmaceuticals, Inc. |
Methods for preparation of bile acids and derivatives thereof
|
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
|
US9908873B2
(en)
|
2015-08-12 |
2018-03-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
|
JP2018526405A
(ja)
|
2015-09-09 |
2018-09-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用
|
|
CA2999302A1
(en)
|
2015-09-24 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation bile acid derivatives
|
|
AU2016350690C1
(en)
|
2015-11-06 |
2020-04-23 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
JP2019510739A
(ja)
|
2016-02-29 |
2019-04-18 |
イーライ リリー アンド カンパニー |
Ｇｆｒａｌ受容体療法
|
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
US10106553B2
(en)
|
2016-04-11 |
2018-10-23 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
|
|
CN109071452A
(zh)
|
2016-04-13 |
2018-12-21 |
英特塞普特医药品公司 |
治疗癌症的方法
|
|
US10654834B2
(en)
|
2016-07-01 |
2020-05-19 |
Venenum Biodesign, LLC |
Non-systemic TGR5 agonists
|
|
WO2018005801A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
|
EP3518937A4
(en)
|
2016-09-30 |
2020-04-29 |
Intercept Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF A BILIARY ACID DERIVATIVE
|
|
WO2018071493A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
|
CN110088089B
(zh)
|
2016-10-25 |
2023-08-29 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途
|
|
US10988433B2
(en)
|
2016-10-25 |
2021-04-27 |
Janssen Pharmaceutica Nv |
Cyclohexyl GPR40 agonists for the treatment of type II diabetes
|
|
JP7008704B2
(ja)
|
2016-11-28 |
2022-01-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
|
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
EP3551651B1
(en)
|
2016-12-09 |
2024-03-06 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
CA3044915A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
US10793530B2
(en)
|
2017-01-26 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
CN110177773B
(zh)
|
2017-01-26 |
2023-08-25 |
勃林格殷格翰国际有限公司 |
苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
|
|
WO2018138029A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
WO2018138030A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
|
CN110214135B
(zh)
|
2017-01-26 |
2023-02-21 |
勃林格殷格翰国际有限公司 |
茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
|
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
|
WO2018146008A1
(en)
|
2017-02-08 |
2018-08-16 |
Boehringer Ingelheim International Gmbh |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
|
JPWO2018181847A1
(ja)
|
2017-03-31 |
2020-03-05 |
武田薬品工業株式会社 |
芳香環化合物
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
|
EP4424362A3
(en)
|
2017-06-16 |
2024-11-27 |
Zealand Pharma A/S |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
BR112019027458A2
(pt)
|
2017-06-23 |
2020-07-07 |
Intercept Pharmaceuticals, Inc. |
métodos e intermediários para a preparação de derivados de ácidos biliares
|
|
CA3071966A1
(en)
|
2017-08-22 |
2019-02-28 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
|
CN111629745A
(zh)
|
2017-11-06 |
2020-09-04 |
夏尔-Nps医药品有限公司 |
用于在手术前、期间或之后投与的glp-2类似物和肽体(peptibodies)
|
|
US11225471B2
(en)
|
2017-11-16 |
2022-01-18 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
MX2020007283A
(es)
|
2018-01-08 |
2020-09-10 |
Celon Pharma Sa |
Derivados de acido 3-fenil-4-hexinoico como agonistas del receptor acoplado a la proteina g-40.
|
|
US20220152164A1
(en)
|
2019-03-22 |
2022-05-19 |
Kallyope, Inc. |
Gpcr combination therapies
|
|
EP3976576A4
(en)
|
2019-05-29 |
2023-06-28 |
Kallyope, Inc. |
Gpr40 agonists
|
|
IL291985A
(en)
|
2019-10-07 |
2022-06-01 |
Kallyope Inc |
Gpr119 agonists
|
|
CA3163243A1
(en)
|
2019-12-03 |
2021-06-10 |
Kallyope, Inc. |
Sstr5 antagonists
|
|
AU2021225966A1
(en)
|
2020-02-28 |
2022-09-15 |
Kallyope, Inc. |
GPR40 agonists
|
|
PH12022552277A1
(en)
|
2020-02-28 |
2024-03-04 |
Kallyope Inc |
Gpr40 agonists
|